Security key
140755109
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA)
CUSIP: 140755109
Q4 2019 13F Holders as of 31 Dec 2019
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 31,365,475
- Total 13F value
- $505,318,090
- Share change
- +403,142
- Put/Call ratio
- 104%
- SEC-reported price per share
- $16.11
- Number of holders
- 146
- Value change
- +$4,578,062
- Number of buys
- 66
- Number of sells
- 57
- Shares outstanding
- 54,790,889
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2019
Institutions
146
Top holders
10
CARA full security history
Ownership snapshot
Full 13F holder table
Tvardi Therapeutics, Inc. SEC filings
Tvardi Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PRICE T ROWE ASSOCIATES I...
Disclosed value leader
PRICE T ROWE ASSOCIATES I...
Comparable rows
15/15
Latest evidence
30 Sep 2019
13F
Lead comparable stake: 8.5%
Showing 1-6 of 15 holder rows.
Quick read
PRICE T ROWE ASSOCIATES INC /MD/ leads the comparable SEC ownership view at 8.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PRICE T ROWE ASSOCIATES INC /MD/'s linked filing trail.
Comparable ownership
Top 5
PRICE T ROWE ASSOCIATES INC /MD/
8.5%
BlackRock Finance, Inc.
6.5%
RHO CAPITAL PARTNERS INC
5.8%
VANGUARD GROUP INC
4%
FARALLON CAPITAL MANAGEMENT, L.L.C.
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
8.5%
|
$84,761,000
4,636,827 shares
|
— | 30 Sep 2019 |
| BlackRock Finance, Inc. |
13F
Company
|
6.5%
|
$64,878,000
3,549,152 shares
|
— | 30 Sep 2019 |
| RHO CAPITAL PARTNERS INC |
13F
Company
|
5.8%
|
$58,369,000
3,193,057 shares
|
— | 30 Sep 2019 |
| VANGUARD GROUP INC |
13F
Company
|
4%
|
$39,716,000
2,172,686 shares
|
— | 30 Sep 2019 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
3.9%
|
$39,302,000
2,150,000 shares
|
— | 30 Sep 2019 |
| FIRST MANHATTAN CO. LLC. |
13F
Company
|
3.4%
|
$34,113,000
1,866,188 shares
|
— | 30 Sep 2019 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2019
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
146
Shares
31,365,475
Rows available
146
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2019 vs Q3 2019 Across Filers
Q3 2019 holders
140
Q4 2019 holders
146
Holder diff
6
| Investor | Q3 2019 Shares | Q4 2019 Shares | Share Diff | Share Chg % | Q3 2019 value | Q4 2019 value | Value change | Value Chg % |
|---|